CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas
Loélia Babin, Elissa Andraos, Steffen Fuchs…·Fabienne Meggetto
The paper identifies circZBTB46 as a driver of crizotinib resistance in ALK-positive lymphomas and shows its targeting restores drug sensitivity.